CVE-2024-35428

Exploitation

Assessed, none found. CISA's assessment recorded neither public exploit code nor evidence of exploitation when it was made.

SSVC decision

• ExploitationnoneCISA recorded no public exploit code and no evidence of exploitation.
• AutomatablenoAt least one step from reconnaissance to exploitation cannot be reliably automated.
• Technical ImpactpartialSuccessful exploitation gives limited control of the vulnerable component.

CISA publishes the decision points, not a final SSVC decision. The decision also depends on mission and well-being impact, which is a property of your deployment rather than of the vulnerability.

EPSS probability

0.78% probability of exploitation activity in the next 30 days.

EPSS percentile

Equal to or higher than the score of 55.6% of scored records. A rank, not a probability.

NVD base score

7.1 (CVSS v3.x), scored by the NVD independently of the CNA.

NVD CVSS vector

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:H

NVD analysis status

Modified. NVD last modified this record on 2026-06-17.

Red Hat severity

No Red Hat rating. Red Hat rates the CVEs that affect its products.

Exploit-prediction scores from FIRST. Independent scoring and analysis status from the NVD. Vendor severity from Red Hat. Exploitation assessment and catalog membership from CISA.

Published

2024-05-30 17:02Z2 YR AGO

Last updated

2025-03-13 14:11Z1 YR AGO

Reserved

2024-05-17

Assigning CNA

mitre

Record state

PUBLISHED

Severity

High (CVSS 7.1)

CNA CVSS vector

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:H

Weaknesses

• CWE-22Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal')Base

Data version

5.1

Document digest

64a3c3a71b76341748faba0fdaded9d6cd85a41d80dd594913e46c580e13af05

• github.comhttps://github.com/mrojz/ZKT-Bio-CVSecurity/blob/main/CVE-2024-35428.md